Profile data is unavailable for this security.
About the company
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
- Revenue in CNY (TTM)19.72bn
- Net income in CNY-6.18bn
- Incorporated2010
- Employees10.47k
- LocationBeigene Ltd94 Solaris Avenue,, Camana BayGRAND CAYMAN KY1-1108Cayman IslandsCYM
- Phone+1 3 459494123
- Websitehttps://www.beigene.com/
Holder | Shares | % Held |
---|---|---|
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 5.04m | 4.38% |
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 4.22m | 3.67% |
Taiping Life Insurance Co. Ltd. (Investment Portfolio)as of 15 Dec 2022 | 2.41m | 2.09% |
Abu Dhabi Investment Authority (Investment Management)as of 15 Dec 2022 | 2.41m | 2.09% |
China International Capital Corp. Ltd. (Invt Management)as of 15 Dec 2022 | 2.07m | 1.80% |
Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 1.62m | 1.41% |
China Fund Management Co., Ltd.as of 31 Dec 2023 | 1.38m | 1.20% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 1.21m | 1.05% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 1.20m | 1.04% |
Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 1.08m | 0.94% |